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Abstract: The aberrant activity of Wnt signaling is an early step in the transformation of normal
intestinal cells to malignant tissue, leading to more aggressive tumors, and eventually metastases.
In colorectal cancer (CRC), metastasis accounts for about 90% of patient deaths, representing the most
lethal event during the course of the disease and is directly linked to patient survival, critically limiting
successful therapy. This review focuses on our studies of the metastasis-inducing gene S100A4, which
we identified as transcriptional target of β-catenin. S100A4 increased migration and invasion in vitro
and metastasis in mice. In patient CRC samples, high S100A4 levels predict metastasis and reduced
patient survival. Our results link pathways important for tumor progression and metastasis: the
Wnt signaling pathway and S100A4, which regulates motility and invasiveness. S100A4 suppression
by interdicting Wnt signaling has potential for therapeutic intervention. As proof of principle, we
applied S100A4 shRNA systemically and prevented metastasis in mice. Furthermore, we identified
small molecule inhibitors from high-throughput screens of pharmacologically active compounds
employing an S100A4 promoter-driven reporter. Best hits act, as least in part, via intervening in
the Wnt pathway and restricted metastasis in mouse models. We currently translate our findings
on restricting S100A4-driven metastasis into clinical practice. The repositioned FDA-approved
drug niclosamide, targeting Wnt signaling, is being tested in a prospective phase II clinical trial for
treatment of CRC patients. Our assay for circulating S100A4 transcripts in patient blood is used to
monitor treatment success.
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1. Wnt Signaling in Colorectal Cancer
In colorectal cancer (CRC), metastasis accounts for about 90% of patient deaths, representing the
most lethal event during the course of the disease. Metastasis is directly linked to patient survival,
and critically limits successful therapy [1,2]. The development of CRC is a sequential process from
normal intestine to adenomatous tissue, adenoma, and finally carcinoma, due to the accumulation of
many molecular changes, like gene mutations, loss of epigenetic control, altered gene expression, and
constitutive activation of cancer related signaling cascades. Important examples that trigger CRC are
adenomatous polyposis coli (APC), Kirsten rat sarcoma viral oncogene homolog (KRAS), β-catenin,
SMAD family member (SMAD) 2/4, metastasis associated in colon cancer (MACC) 1, programmed cell
death (PDCD) 4, tumor suppressor protein p53, and the unbalanced Wingless-type MMTV integration
site family (Wnt) signaling pathway [1,3–7].
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Wnt-mediated signaling is one of the crucial signaling pathways in CRC. The molecular
composition of the Wnt pathway and its role in signal modulation has been reviewed extensively
in the last few years [7–10], and will also be described here in brief (see Figure 1). In humans
19 evolutionary conserved Wnt genes exist [11]. The Wnt proteins bind to various receptors and
activate receptor specific downstream signaling. Mainly, Wnt-mediated pathway activity can be
defined as either canonical (i.e., β-catenin dependent) or non-canonical (i.e., β-catenin independent)
signaling, subgrouped in non-canonical planar cell polarity (PCP) and non-canonical Wnt/calcium
pathway. However, cross-talk downstream of both pathway classes is reported, based on the availability
of extracellular Wnts, cellular context, and the types of Wnt receptor [11].
Cancers 2016, 8, 59                                      2 of 21 
 
SMAD family member (SMAD) 2/4, metastasis associated in colon cancer (MACC) 1, programmed 
cell  death  (PDCD)  4,  tumor  suppressor  protein  p53,  and  the  unbalanced Wingless‐type MMTV 
integration site family (Wnt) signaling pathway [1,3–7]. 
W t‐mediated  signaling  is  one  of  the  cruc al  signaling  pathways  in  CRC.  The  molecular 
composition of the Wnt pathway and its r le in signal modulation has been reviewed  xtensively in 
the  last  few  years  [7–10],  and will  also  be  described  here  in  brief  (see  Figure  1).  In  humans  19 
evolutionary conserved Wnt genes exist [11]. The Wnt proteins bind to various receptors and activate 
receptor specific downstream signaling. Mainly, Wnt‐mediated pathway activity can be defined as 
either canonical (i.e., β‐catenin dependent) or non‐canonical (i.e., β‐catenin independent) signaling, 
subgrouped  in non‐canonical planar cell polarity (PCP) and non‐canonical Wnt/calcium pathway. 
However, cross‐talk downstream of both pathway classes  is reported, based on  the availability of 
extracellular Wnts, cellular context, and the types of Wnt receptor [11]. 
 
Figure 1. Schematic representation of the Wnt signaling pathway and possible points for therapeutic 
interventions  to  restrict  S100A4‐mediated  tumor  progression  and  metastasis.  Possible  therapeutic 
intervention points downstream of active Wnt signaling complexes act via reducing β‐catenin levels, 
lowering its nuclear accumulation, and/or inhibiting the formation of active target gene (here S100A4) 
transcription complexes by small molecules. The expression of specific target genes, such as S100A4, can 
be reduced by targeting its mRNA level by RNAi. Inhibition of intracellular S100A4 protein function is 
possible via small molecules. Inhibition of extracellular S100A4 can be achieved with S100A4‐specific 
antibodies, interactions with its receptor (here RAGE) by using receptor‐specific antibodies. 
Without active signaling, β‐catenin has a  rather  short half‐life  in  the cytoplasm,  since  it gets 
phosphorylated by the so called “destruction complex”, consisting of glycogen synthase kinase (GSK) 
3β, casein kinase (CK) Iα, Axin, and APC, subsequent ubiquitinylation and eventual degradation by 
the proteasome [9]. 
Figure 1. Schematic representation of the Wnt signaling pathway and possible points for therapeutic
interventions to restrict S100A4-mediated tumor progression and metastasis. Possible therapeutic
intervention points downstream of active Wnt signaling complexes act via reducing β-catenin levels,
lowering its nuclear accumulation, and/or inhibiting the formation of active target gene (here S100A4)
transcription complexes by small molecules. The expression of specific target genes, such as S100A4, can
be reduced by targeting its mRNA level by RNAi. Inhibition of intracellular S100A4 protein function is
possible via small molecules. Inhibition of extracellular S100A4 can be achieved with S100A4-specific
antibodies, interactions with its receptor (here RAGE) by using receptor-specific antibodies.
Without active signaling, β-catenin has a rather short half-life in the cytoplasm, since it gets
phosphorylated by the so called “destruction complex”, consisting of glycogen synthase kinase (GSK)
3β, casein kinase (CK) Iα, Axin, and APC, subsequent ubiquitinylation and eventual degradation by
the proteasome [9].
The canonical Wnt pathway is triggered by the interaction of Wnt with the Frizzled receptor
and the co-receptors low-density lipoprotein receptor-related proteins (LRP) 5/6. This inactivates the
β-catenin destruction complex, when Axin is recruited by the segment polarity protein dishevelled
homolog (Dvl) to the activated Wnt/Frizzled/LRP complex. β-catenin starts to accumulate in the
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cytoplasm and eventually translocates into the nucleus, where it activates the transcription of target
genes under the control of a T-cell factor (TCF) binding motif along with other factors [12].
The activation of the Wnt signaling pathway is tightly controlled at the cell surface. Secreted
Wnt-antagonists of the Dickkopf (DKK) family form a ternary complex by binding to the DKK receptor
family Kremen (Krm) and the Wnt co-receptor LRP5/6, thereby inhibiting the formation of active
Wnt/Frizzled/LRP signaling complexes [13]. The tight control of Wnt/β-catenin signaling is disrupted
by an aberrant overexpression of Wnt ligands, mutations in interacting motifs of destruction complex
molecules, or mutations in β-catenin itself [9,14,15]. The key regulator of the destruction complex,
APC, is mutated in around 80% of the CRC tumor specimens [16]. The destruction complex is also
inactivated, when frameshift mutations occur in Axin2 [17]. Besides this, 15% of the remaining CRC
tumor specimens harbor mutations in β-catenin [18]. The most important mutations in β-catenin occur
at the amino acid S45 in exon 3, which is phosphorylated by CK1α and at S33, S37, T41, which get
phosphorylated by GSK3β in the active destruction complex. When phosphorylation at these sites is
not possible, either by loss of the destruction complex or mutation of crucial phosphorylation sites,
β-catenin will not be triggered for proteasomal degradation and will induce aberrant Wnt signaling
target gene transcription [1,19].
2. S100A4
The S100 calcium binding protein A4 was first discovered by Ebradlize and colleagues in 1989
and was initially named metastasin (mts1) [20]. Already in this initial report, the metastatic potential
of S100A4 was unveiled. Later, it was independently cloned by several groups and several names
were given, such as fibroblast-specific protein (FSP1), 18A2, pEL98, p9Ka, 42A, CAPL, and calvasculin
(reviewed in [21]).
2.1. S100—Family and Function
S100A4 belongs to a family of S100 proteins, named due to their solubility in saturated ammonium
sulfate. The first member of the group of S100 proteins was described back in 1965 by Moore [22].
Currently, more than 20 proteins that belong to this gene family are known. Most of them can be found
at human chromosome 1 (1q21), where they form two clusters, containing S100A1-9 and S100A12-16
at one locus, and S100A10 and 11 at another position [23]. The remaining coding sequences for S100
proteins can be found on different chromosomes throughout the genome, including the X chromosome.
S100 proteins are a highly similar group of small Ca2+ binding proteins with a molecular mass of
10–12 kDa, which share 50% of their amino acid sequence. This high degree of homology suggests
a common ancestor, that might have evolved 500 million years ago [24]. All S100 proteins share an
EF hand motif as common structural feature. The S100 proteins act as homo- or heterodimers, or
can form oligomers, as exemplified by S100A4. Each monomer contains two EF hand motifs, that
in most cases are Ca2+ binding helix-loop-helix domains [25]. The N-terminally located domain
(pseudo EF hand) is composed of 14 amino acids while the C-terminal canonical EF hand is built of
12 amino acid residues. The latter binds Ca2+ with higher affinity [26]. Binding of Ca2+ to the EF
hand motif results in a movement of the two helices giving access to hydrophobic protein-protein
interaction sites, which were previously hidden in the protein structure. The Ca2+ bound S100 proteins
are regarded as ”open” and constitute the active form [27,28]. S100 proteins have been shown to be
involved in numerous different cellular functions, e.g., proliferation, differentiation, apoptosis, calcium
homeostasis, metabolism, inflammation and motility (reviewed in [29]). All S100 family members have
no known enzymatic activity and exert their role via interaction with and regulation of other proteins.
Depending on the given S100 protein, they can act intracellularly, in the extracellular space, or in both
compartments [30].
Most of the S100 family members are involved in or initiating biological functions contributing to
malignant disease such as proliferation, metastasis, angiogenesis and immune evasion. These proteins
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represent promising candidates for cancer diagnosis and prognosis as well as therapeutic targets with
first inhibitors already identified and tested in clinical trials (reviewed in [31]).
2.2. S100A4—a β-Catenin Target Gene
Since Wnt signaling activity is altered in almost all CRC tumors, we addressed the question,
which genes are modified in their expression by a gain-of-function (GOF) mutation in β-catenin [32].
We performed a gene expression profile analysis with the human CRC cell line HCT116 (heterozygous
of wt and ∆45-mutant β-catenin, lacking serine 45) and HAB-92wt cells, a HCT116 derived cell
line expressing monoallelic wt β-catenin [32]. In this array we observed 40-fold increase of S100A4
expression in HCT116 cells, compared to HAB-92wt cells. This result was confirmed in HCT116-derived
cell lines HAB-68mut, expressing monoallelic ∆45-mutant β-catenin, and NCI-H28null, nullosomic for
β-catenin, verifying, that functionally active β-catenin is necessary for S100A4 induced expression
in CRC. Forced overexpression or knock-down of S100A4 and/or mutated β-catenin further proved,
that transcriptionally active β-catenin enhances the S100A4-induced migration and invasion of
HCT116, HAB-92wt and NCI-H28null cells. In a CRC xenograft mouse model, intrasplenic or
intracardiac transplantation of HAB-92wt cells, with or without stable mutant β-catenin expression,
demonstrated that due to GOF in the mutant β-catenin, this group showed more metastatic lesions
in liver and lungs, compared to vector control cells. With this evidence we have designed a
comprehensive study to determine whether S100A4 is a direct transcriptional target of β-catenin.
Sequence analysis of the human S100A4 promoter revealed a putative TCF binding motif at ´679 to
´673. Luciferase experiments with or without TCF binding site mutations showed that S100A4 is a
direct transcriptional target of β-catenin. Further, the binding of β-catenin to the S100A4 promoter
was confirmed by electrophoretic mobility shift assays (EMSA) and chromatin immunoprecipitation
(ChIP) analysis [32]. This data suggests that S100A4 is indeed a direct transcriptional target of the
Wnt/β-catenin/TCF-mediated signaling pathway, strongly suggesting novel therapeutic interventions
or screening for pharmacologically active compounds to reduce S100A4 expression in CRC.
2.3. S100A4 in Non-Malignant Disease
S100A4 is associated with both non-malignant and malignant human diseases. Several groups
have reported a role of S100A4 in inflammation. Human articular chondrocytes upregulate S100A4
expression levels during rheumatoid- and osteoarthritis. Elevated S100A4 levels lead to increased
phosphorylation of protein tyrosine kinase (Pyk)-2, mitogen-activated protein (MAP) kinases, and
activated nuclear factor kappa-light-chain-enhancer of activated B cells (NFκB), that in turn results
in elevated matrix metalloproteinase (MMP)-13 secretion. These effects are mediated at least in part
via the receptor for advanced glycation end products (RAGE), as the inhibition of RAGE resulted
in decreased S100A4 dependent signaling [33]. When analyzing bone material from patients with
osteoarthritis, by employing microarrays and quantitative PCR, the authors show an upregulation of
S100A4, but also other Wnt-related genes [34]. S100A4 was also shown to be commonly overexpressed
in cardiac hypertrophy [35]. The expression of S100A4 in this model tissue injury was linked to general
elevated expression of cell growth related proteins, leading to tissue remodeling during reconstitution
of the myocardium. Here S100A4 acts as growth factor and pro-survival factor in the myocard [36].
Later, the role of S100A4 during cardiomyogenesis was described in vitro [37].
2.4. S100A4 in Cancer
The cellular functions of S100A4 were mainly characterized in cancer, promoting tumor
progression and metastasis formation, reviewed by Boye and Mælandsmo, and recently by Bresnick
and colleagues [31,38]. Enhanced cell growth and motility upon elevated S100A4 expression increases
the metastatic potential of cancer cells originating from many entities, like breast, lung, prostate, bone,
and cancers from the digestive tract, in vitro and in mice [31]. The expression level of S100A4 in tumors
of cancer patients also correlates with enhanced progression and metastasis formation, emphasizing
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its importance in clinical cancer diagnosis. This has been observed for many cancer types, including
bladder cancer [39], breast cancer [40], lung squamous cell carcinoma [41], pancreatic carcinoma [42],
gastric [43], and colorectal cancer [32]. S100A4 expression in cancer, besides the above mentioned
Wnt/β-catenin pathway, is mediated by the receptor tyrosine-protein kinase erbB (ERBB) 2, which
upregulates S100A4 via extracellular signal-regulated kinase (ERK) signaling in medulloblastoma [44].
Interestingly, this mechanism might lead to a feed-forward loop in S100A4 expression regulation, since
extracellular S100A4 itself was reported to stimulate ERBB2 receptor signaling [45]. S100A4 expression
in breast cancer also depends on integrin signaling via the proto-oncogene tyrosine-protein kinase Src
and nuclear factor of activated T-cells (NFAT) 5, specifically using integrin α6β4 response to epithelial
mesenchymal transition (EMT), promoting cell motility [46,47].
EMT is an important step in cancer development, characterized by aberrant signaling activities,
including the Wnt pathway (reviewed in [48]). Before S100A4 was known as a Wnt signaling target
gene, its expression was reported to be an early factor involved in the process of EMT in epithelial
cells [49]. The role of S100A4 in tumor progression and metastasis via induction of EMT has been
confirmed in many types of cancers, including CRC [50–53]. There, S100A4 and also β-catenin were
found higher expressed in the tumor invasive margin [53,54].
When focusing on the molecular mechanisms of S100A4 and its role in cancer, a number of cancer
related protein-protein interaction partners have been described, including cytoskeletal proteins such
as actin, myosin, and tropomyosin (reviewed in [27]). An important example for S100A4-induced
motility is mediated via its interaction with non-muscle myosin-II, where S100A4 can negatively
regulate polymerization of myosin-IIA filaments by interacting with the C-terminal part of its heavy
chain [55,56]. A higher disassembly rate of myosin-IIA filaments, especially at leading edges of
migrating cells, contributes to cell motility and metastasis formation [57]. A very recent aspect of
S100A4-dependent mechanisms at the plasma membranes of tumor cells has been published by Jaiswal
and colleagues. The authors describe the repair of lesions at the plasma membrane as a critical
mechanism for migrating and invading cancer cells, subjected to altered membrane stability and
higher mechanical tension. Injuries at the membranes are followed by an influx of extracellular Ca2+,
which in turn triggers the fusion of non-secretory vesicles to seal the wound and the shedding of
the injured part [58]. Interestingly, important factors of the repair mechanism, like Ca2+-binding
annexin A2, filamentous (F-) actin and myosin II, which were described to establish the wound closure
in cooperation with S100A11, were also reported to interact with S100A4 [27,58]. Indeed, accumulated
S100A4 has been found at sites of plasma membrane repair, pointing to a role of S100A4 in maintaining
the invasive potential of tumor cells [58].
S100A4 is also secreted into the intercellular fluid—by the tumor cell itself or by cells in the local
tumor environment—and can exert multiple functions by interaction with receptors like RAGE [59–61].
RAGE-mediated signaling by extracellular S100A4 leads to nuclear translocation of intracellular
S100A4, linking extracellular protein levels to intracellular responses [62]. Besides this, S100A4-induced
but RAGE-independent effects can be shown under RAGE negative conditions, e.g., neurite outgrowth,
cell motility, and capillary like growth [63–65]. For CRC, our group described the hyperactivity of
hypoxia response and ERK signaling, leading to increased cellular motility [66]. But also newer reports
link S100A4-mediated RAGE signaling to an increase in metastatic potential in cancer, like thyroid
cancer and melanoma [67,68].
Taken together, it is well established that S100A4 has profound impact in many types of solid
cancers, where its upregulation causes tumor progression and metastasis formation. S100A4 expression
levels in tumors are considered as a biomarker for the prognosis of both metachronous metastasis and
survival of cancer patients.
2.4.1. Prognostic Value of S100A4 in CRC Tissue
When looking at CRC prognosis in general, there is a decrease of the 5-year survival rate of CRC
patients after resection of the primary tumor from approximately 85%, when tumors were diagnosed
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at stages I and II, to less than 50%, when lymph node metastases occurred (stage III) [69]. In case
of distant metastases at time of diagnosis (stage IV), the 5-year survival rate of CRC patients drops
to less than 10% [2]. A meta-analysis of eight studies analyzing the prognostic value of S100A4
expression on overall and disease-free survival in CRC consolidates the correlation of high S100A4
expression in tumor tissues with low survival rates of the patients [70]. We analyzed CRC patients
with previously non-metastasized primary tumors with regard to their S100A4 expression in the
tumors and their disease prognosis. Immunohistochemical staining of S100A4 in tumor tissue and
gene specific quantification of micro-dissected S100A4-mRNA by quantitative reverse-transcription
(q-RT) PCR showed higher S100A4 expression in patients, who developed metachronous metastases
within 36 months. Overall and metastasis-free survival of patients with S100A4 expressions in the
primary tumors above the calculated cut-off were significantly shorter than for patients with low
S100A4 expression [32]. A similar analysis was performed in a cohort of 60 CRC patients of stages
I-III. Again, S100A4 expression in primary tumors was higher in patients with metastases after tumor
resection, and both the overall and metastasis free survival differed significantly, depending on the
S100A4 expression [66]. The intracellular and intratumoral distribution of S100A4 proteins is also of
prognostic value, as nuclear localization of S100A4 increases the risk for poor survival and metastasis
formation in stage II CRC patients [71]. Further, the expression of S100A4 in the advancing tumor
front can be used as an independent indicator for overall survival [72].
Today, S100A4 expression in tumor tissue is a valid and valuable biomarker for determining the
risk for metastasis formation of CRC patients, and much effort is made to evaluate S100A4 expression
in tumors as a predictor for therapy response.
2.4.2. Diagnostic and Prognostic Value of Circulating S100A4 Transcripts in Patient’s Blood
The link of reported prognostic value of high S100A4 levels in the primary tumor for metachronous
metastasis and reduced patient survival, documented in a large body of studies, is mainly based on
snapshot analyses due to tissue availability. Thus, we established for the first time a non-invasive,
plasma-based assay for the quantification of circulating S100A4 transcripts in blood of colon, rectal,
and gastric cancer patients, that allows clinical application routinely for diagnosis, prognosis and for
monitoring treatment success [73]. We determined increased S100A4 transcripts in cancer patients
of each entity and all disease stages, compared with tumor-free volunteers, with sensitivities of
96%, 74%, and 90% and specificities of 59%, 82%, and 71%, for colon, rectal, and gastric cancer
patients, respectively. In prospectively analyzed follow-up patients, higher S100A4 levels were
found in those patients who later experienced metastasis, compared with patients without metastasis.
In high S100A4-expressing patients, disease-free survival was decreased. Thus, we demonstrated the
diagnostic and prognostic potential of this plasma-based assay for early defining patients’ risk for
metastasis. Currently, we are employing this assay for monitoring circulating S100A4 transcripts levels
to assess the treatment responses in a clinical phase II trial.
Combinatorial detection of relevant transcripts might even enhance diagnosis, prognosis, and/or
prediction for cancer patients. Thus we combined detection of circulating transcripts of S100A4
with those of the MACC1 gene for CRC and gastric cancer patients [74,75]. We discovered the gene
MACC1 in 2009 [76]. It is meanwhile acknowledged as prognostic and predictive biomarker for tumor
progression and metastasis linked to patient survival for a broad variety of solid tumor entities [77,78].
S100A4 as Wnt/β-catenin target gene [53,54] as well as MACC1 [79] were independently found at the
tumor invasion front in CRC patients. Both genes are considered to be crucially involved in CRC liver
metastasis [80]. When combining S100A4 with circulating transcripts of MACC1, improved survival
prediction was seen for newly diagnosed CRC as well as gastric cancer patients [74]. Interestingly, a
combination with β-catenin levels might also be an option, since increased levels of β-catenin have
also been determined in CRC patient plasma correlating with tumor stage [81]. Very recently, Barbazan
and colleagues reported the prognostic relevance of a S100A4/MACC1 cluster in circulating tumor
cells for progression-free and overall survival of patients with metastatic CRC [82].
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3. Therapeutic Interventions of S100A4-Mediated Tumor Progression and Metastasis
Elevated S100A4 expression is altering the genetic expression pattern of cells, leading to a more
malignant phenotype [38]. For CRC patients, higher tumor stages at time of diagnosis and the risk to
develop metastases are drastically shortening their life span. Therefore, there is a need for therapeutic
options to either reduce the expression level of S100A4 in the tumor or its environment, or to interfere
with downstream effects of the protein, like protein-protein interactions and signaling pathway
modulation. Applicable methods to reduce the S100A4-dependent metastatic potential include the
knock-down of S100A4-mRNA via RNAi or the therapy with small molecules, screened for interfering
in cellular S100A4 functions or S100A4 promoter activity. With the focus on Wnt signaling, we will
review drugs, which affect S100A4 expression by inhibiting this very crucial pathway.
3.1. RNAi-Based Knock-Down of S100A4 Expression
Early attempts to reduce the mRNA and protein level of S100A4 in the late 1990s reported
successful reduction of the S100A4-induced metastatic phenotype for osteosarcoma, in vitro as well as
in vivo [83]. Ribozyme-based knock-down of S100A4 in cultured CRC cells verified the decrease of
cellular motility. The reduction in S100A4 protein levels also altered the cellular matrix remodeling
genes, like MMPs and tissue inhibitors of metalloproteinases (TIMPs), responsible for the invasion of
cancer cells into surrounding tissues. In cell culture, S100A4-specific siRNA reduced the expression
MMP-9 and MMP-10, but increased TIMP-4 [84]. Our group also found reduced MMP-9 levels in
tumors of CRC xenografted mice, after hydrodynamics-based systemic treatment with plasmids
coding for S100A4-specific shRNA, via repeated tail vein injection [85]. This treatment also decreased
the formation of liver metastases significantly in those animals, verifying the role of S100A4 in
CRC metastasis formation [32]. Additionally to cellular invasion, increased angiogenesis has been
found in S100A4-related cancer, when extracellular S100A4 binds to the endothelial plasminogen
co-receptor annexin 2 and plasminogen itself [86]. Other reports link extracellular S100A4 to vascular
endothelial growth factor (VEGF) expression and metastasis formation [87,88]. But also the RNAi-based
knock-down of S100A4 directly in thyroid cancer cells reduced VEGF expression, in addition to MMP-9,
and thus invasion and angiogenesis [89]. For CRC, the connection of S100A4 overexpression and
elevated VEGF levels, resulting in increased viability and migration, was reported recently [90].
Taken together, the reduction of S100A4 expression, either in the tumor itself or in its environment,
has been proven to reduce the metastatic potential of CRC, shown by decreased cell motility in vivo, as
well as in less metastasis formation in vivo. Applying RNAi-based therapeutics to decrease S100A4
expression in the clinic might be an approach to reduce the metastatic burden of CRC patients and
may prolong their disease-free survival.
3.2. Sulindac
Sulindac is long known as a nonsteroidal anti-inflammatory drug (NSAID), which inhibits the
cyclooxygenase (COX) activity of the prostaglandin endoperoxide synthase (PTGS1 and PTGS2)
enzyme that is involved in inflammation processes by converting arachidonic acid to prostaglandin
H2. However, in the 1970s it came into focus that such drugs, including sulindac, also exert anti-tumor
effects, which was repeatedly confirmed by clinical studies [91,92]. The sulindac metabolite sulindac
sulfide, which is generated in the liver, is responsible for this anti-tumor and chemopreventive
action [93].
3.2.1. Sulindac and Wnt Signaling
More detailed studies on the molecular mechanism of action of sulindac revealed that the
anti-tumor and the chemopreventive activity of this compound is rather COX-independent, as
shown in different cancer cell lines with varying levels of COX-expression [94]. More interestingly,
these anti-tumor effects of sulindac have been linked to its intervention with Wnt signaling,
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namely β-catenin transcriptional activity in association with reduced nuclear accumulation or
reduced non-phosphorylated levels of β-catenin [95,96]. This link was further supported by the
chemopreventive activities of sulindac in the rodent azoxymethane carcinogen model, which closely
resembles the clinical situation of β-catenin and APC mutant colon cancers [97,98]. In line with this,
clinical trials with sulindac have shown significant reduction in colorectal polyps in familial and in
sporadic adenomatous polyposis patients [99,100]. In fact these data paved the ground for analyzing
the anti-tumor and anti-metastatic efficacy of sulindac in the context of S100A4, as one attractive target
of the Wnt signaling pathway [32].
3.2.2. Sulindac as a S100A4 Inhibitor
In our studies we also used the pharmacological inhibitor sulindac known to intervene in the
Wnt signaling pathway. We demonstrated the reduction of β-catenin-mediated S100A4 activation
and expression in GOF as well as in loss of function (LOF) β-catenin variant carrying human CRC
cell lines treated with sulindac [101]. The property of increased cellular migration and invasion in
GOF lines was decreased by 30% to 60% with sulindac treatment. The expression knock-down of
β-catenin by sulindac led to its reduced nuclear accumulation and to reduced binding of β-catenin to
TCF-4. This resulted in decreased S100A4 promoter activity and S100A4 expression. This correlated
well with inhibition of cell migration and invasion, which was rescued by ectopic cytomegalovirus
(CMV)-promoter driven S100A4 overexpression. Sulindac administration in mice, intrasplenically
transplanted with colon cancer cells which were transfected with mutant β-catenin, revealed reduced
tumor growth and metastasis formation compared with solvent treated control animals. Sulindac
treatment resulted in significantly reduced β-catenin as well as S100A4 mRNA and protein levels in
the spleen tumors, compared to solvent treated controls. Also in the liver metastases, β-catenin
and S100A4 levels were lowered by sulindac treatment. These in vitro and in vivo experiments
demonstrate that S100A4-mediated tumor progression and metastasis formation, driven by β-catenin
signaling, can be mitigated with administration of sulindac. This further exemplifies the effective
interference of a NSAID compound in Wnt signaling as anti-tumor and anti-metastatic mode of
action. The attractiveness of such an approach is supported by the fact, that meanwhile new sulindac
derivatives such as sulindac-benzylamine were developed, which also inhibit colon cancer cell growth
by suppression of transcriptional activity of β-catenin [96]. Another derivative, NOSH-sulindac, a
nitric oxide- and hydrogen sulfide-releasing hybrid, has been reported recently, which also exerts
anti-tumor activities in numerous cancer cell lines [102].
3.3. Novel Transcriptional Inhibitors of S100A4
The knowledge on the importance of S100A4 for metastasis formation and its involvement in
the Wnt signaling pathway is the driving force for continued search for novel inhibitors. This search
is accelerated by the use of high throughput assays, which provide the technological platform to
identify promising new drug candidates from drug libraries [103]. Such libraries may contain already
known and FDA-approved drugs or encompass large numbers of novel compounds with quite
unknown activities.
Regarding the Wnt target S100A4, the key prerequisite for high throughput screening (HTS) was
the availability and molecular characterization of the human S100A4 promoter to create the appropriate
luciferase-reporter system for the drug screens. The analysis of the S100A4 promoter revealed its link
to the Wnt signaling pathway at transcriptional level by the identification of TCF-4 binding sites as
functional units of TCF-4/β-catenin-mediated regulation of this gene. For identification of S100A4
transcription inhibitors we performed HTS, using the Library of Pharmacologically Active Compounds
(LOPAC) of FDA-approved compounds [104,105]. We employed a CRC cell line stably expressing a
human S100A4-promoter driven luciferase reporter gene construct (HCT116/pS100A4-LUC) to screen
the library. Those compounds were considered active, which did significantly and specifically reduce
S100A4 promoter-driven luciferase expression at preferably low drug concentration and lowest toxicity.
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The initial HTS, which generated promising hits for active compounds, was followed by validation
screens, providing more detailed information on exact values of drug concentration ranges for proper
reporter expression inhibition and more precise definition of the respective half maximal effective
concentration (EC50) values. By this HTS-based workflow two drug candidates were identified,
which possessed high inhibitory efficacy of S100A4 expression: the antibiotic calcimycin and the
anti-helminthic niclosamide.
3.3.1. Calcimycin
Using the HTS approach with the S100A4-promoter driven reporter assay the polyether antibiotic
drug calcimycin was identified with effective inhibitory activity [106,107]. Further analysis of the
calcimycin action in HCT116 human CRC cells revealed the transcriptional inhibition of S100A4
expression in a concentration- and time-dependent manner. Similar calcimycin-mediated effects were
seen in other human colon cancer cell lines. This observation is paralleled by the previous report
that calcimycin is also able to reduce S100A4 expression in mammary adenocarcinoma cells, as well
as in monocytes and lymphocytes [108]. This inhibition of S100A4 expression resulted in reduced
proliferation, colony formation, and migratory activity of the calcimycin-treated cells. The respective
rescue experiments with ectopic CMV-promoter driven overexpression of S100A4 indicated that the
calcimycin action is indeed based on the transcriptional inhibition of this gene. The study further
revealed the link of calcimycin activity and its potential to intervene in the constitutively active Wnt
pathway [109], with other Wnt target genes such as cyclin D1, c-myc, and DKK-1 also being reduced
by the drug. Due to the fact that S100A4 is tightly associated with metastasis formation, we also
performed in vivo studies in mice after intrasplenical application of calcimycin-treated CRC cells to
analyze its anti-metastatic activity. These studies showed that calcimycin reduced metastasis formation
to 30% compared with control mice. Via bioluminescence imaging and immunohistochemistry, smaller
and less frequent liver metastases were seen in the calcimycin treated animals. S100A4 levels in the
metastases were also reduced by calcimycin. These in vivo studies provide strong indication, that the
calcimycin-mediated reduction of S100A4 expression is able to restrict metastasis formation in vivo via
transcriptional inhibition [106].
3.3.2. Niclosamide
Out of the 1280 well-characterized small molecules of the LOPAC library we identified niclosamide
as the most efficient inhibitor of S100A4 promoter activity. Niclosamide is an anti-helminthic drug
and is approved for human use since the middle 1960s. It restricts glucose uptake, oxidative
phosphorylation and anaerobic metabolism in its target cells [110]. Niclosamide acts as a teniacide and
belongs to most essential drugs needed for basic health [111].
Niclosamide as Transcriptional S100A4 Inhibitor
Selecting a candidate drug from the HTS is dependent on the ratio of luciferase activity inhibition
and cell viability. Niclosamide inhibited luciferase activity at 0.78 µM and higher concentrations, but
reduced cell viability at 3.1 µM and higher concentrations. For target gene validation, we analyzed
the concentration- and time-dependency of niclosamide to modify endogenous S100A4 mRNA and
protein levels in cell culture. To achieve the maximum S100A4 expression inhibition accompanied by
minimum toxicity, we went further with a daily application of 1 µM niclosamide resulting in constantly
reduced S100A4 expression. Since S100A4 is a major inducer of cell motility, we tested for the effects of
niclosamide on S100A4-induced migration and invasion in a panel of human CRC cells. Niclosamide
reduced significantly migration, invasion and also impaired wound closure in a wound healing assay
in the different CRC cell lines, compared to solvent-treated controls. In rescue experiments using
ectopically CMV-promoter driven S100A4 overexpressing CRC cell lines, neither reduction of S100A4
expression nor of cell motility inhibition was seen after niclosamide treatment. Niclosamide also
inhibited anchorage-dependent and -independent proliferation of the CRC cells, however, this effect
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was—in contrast to the inhibition of cell motility—not S100A4-specific. Thus, niclosamide inhibited
S100A4-dependent cell motility and invasiveness in CRC cells.
Further, we demonstrated that niclosamide restricted liver metastasis formation by using an
intrasplenically xenografted mouse model. Niclosamide was administered intraperitoneally on a daily
basis. Tumor growth and metastasis development was monitored by non-invasive in vivo luminescence
imaging and at the experimental endpoint at day 22 by ex vivo imaging of the isolated organs spleen and
liver. Whereas solvent-treated control mice formed metastases in the livers, no metastasis development
was seen in niclosamide-treated animals. In the spleen tumors of the niclosamide-treated mice,
expression of S100A4 was reduced indicating that niclosamide reduced S100A4 levels in vivo as well.
We also investigated metastasis formation in vivo under continuous and discontinuous (until day 24,
then solvent-treated until day 50) niclosamide treatment. Both niclosamide-treated mouse groups
showed enhanced overall survival compared with the solvent-treated mice linked to long-term
inhibition of tumor growth and liver metastasis formation, and to reduction of S100A4 expression.
No statistically significant differences were found between the continuously and discontinuously
treated animals. We conclude that niclosamide has the potential for the clinical treatment or prevention
of CRC metastasis in humans.
Niclosamide and Wnt Signaling
A large variety of studies demonstrated actions of niclosamide as anti-cancer agent in different
tumor entities, including CRC, breast cancer, prostate cancer, ovarian cancer, non-small cell lung
cancer (NSCLC), glioblastoma, osteosarcoma, multiple myeloma, and leukemia. There is growing
evidence that anti-cancer actions of niclosamide are predominantly mediated via the Wnt/β-catenin
signaling pathway, which is known to represent a major regulatory pathway for cancer initiation,
growth, cell differentiation and metastasis [9]. With more than 90% of all the CRC patients harboring
mutations in the Wnt/β-catenin signaling pathway, drugs intervening in this pathway came into focus.
This anti-cancer drug repositioning is described for the anti-helminthic drug niclosamide for several
tumor entities [112].
We also analyzed the effect of niclosamide on the Wnt signaling pathway since we identified
the metastasis inducing gene S100A4 as a transcriptional target gene of Wnt/β-catenin signaling [32].
We used HCT116 CRC cells, heterozygous for mutated β-catenin and constitutively active in Wnt
signaling and S100A4 expression, as well as isogenic subline derivatives thereof carrying exclusively the
mutant or the wildtype β-catenin allele. Treatment with 1 µM niclosamide significantly reduced Wnt
pathway activity, S100A4 expression, and consistently, reduced cell migration rates. Since we did not
observe altered nuclear levels of β-catenin following niclosamide treatment, we analyzed for formation
of the β-catenin/TCF activating complex. We found by EMSA and ChIP that treatment of CRC cells
with increasing concentrations of niclosamide interrupted the β-catenin/TCF/oligonucleotide complex
in a concentration-dependent manner, leading to its disappearance at concentrations of 1 µM. Taken
together, niclosamide treatment inhibited the formation of β-catenin/TCF complex, thereby inhibiting
the transcription of the Wnt/β-catenin target gene S100A4.
Also by employing libraries of FDA-approved drugs by HTS, Chen and colleagues identified
niclosamide as a drug able to interfere with the Wnt signaling pathway. They demonstrated that
niclosamide is able to inhibit Wnt/Frizzled-1 signaling in osteosarcoma cells [113,114]. They showed
enhanced Frizzled-1 endocytosis, downregulated Dvl2 protein, thereby inhibiting Wnt3A-stimulated
β-catenin stabilization and lymphoid enhancer-binding factor (LEF)/TCF reporter activity. They
conclude that niclosamide may serve as a negative modulator of Wnt/Frizzled-1 signaling by
depleting upstream signaling molecules. DiRenzo and colleagues showed recently that using
niclosamide as Frizzled receptor inhibitor for blocking Wnt signaling abolished transforming
growth factor (TGF)-β/SMAD3-induced β-catenin stabilization, influencing smooth muscle cell
proliferation [115]. Lu and colleagues analyzed the effect of niclosamide on the essential Wnt
co-receptor for Wnt/β-catenin signaling, LRP6 [116]. They showed in HEK293 cells and in human
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prostate and breast cancer cells, that niclosamide suppressed LRP6 expression and phosphorylation,
blocked Wnt3A-induced β-catenin accumulation, and inhibited Wnt/β-catenin signaling, resulting in
induced apoptosis and anti-cancer activity with half maximal inhibitory concentration (IC50) values
less than 1 µM. They concluded that niclosamide has potential as chemopreventive and therapeutic
agent for human cancer. Osada and colleagues demonstrated anti-proliferative actions of niclosamide
in CRC cells regardless of mutations in APC [117]. This effect was mediated via downregulation
of the Wnt signaling pathway. In particular, they showed a decreased expression of Dvl2, leading
to reduced downstream β-catenin signaling. In CRC xenografted mice, the authors described a
tumor control by orally applied niclosamide treatment and suggest clinical reposition of the drug
niclosamide for CRC treatment. Niclosamide effects were also analyzed in hepatoma cells, since Wnt
signaling plays also a role in hepatocarcinogenesis [118]. The authors showed reduced cell proliferation
following niclosamide treatment, induction of apoptosis, decreased TOP activity, and decreased
levels of β-catenin, Dvl2 and cyclin D1. They summarize that niclosamide is a potential candidate
for hepatoma treatment. Ono and colleagues reported that niclosamide inhibited proliferation of
primary human leiomyoma cells in a dose-dependent manner [119]. Niclosamide-induced proliferation
reduction was not related to decreased cell survival due to similar lactate dehydrogenase (LDH) activity
levels. The authors showed that niclosamide inhibited the Wnt/β-catenin pathway activation in the
human leiomyoma cells by inhibiting the TOP activity and down-regulated pathway target genes like
Axin2. Further, they demonstrated reduced nuclear β-catenin translocation after niclosamide treatment.
Londoño-Joshi and colleagues demonstrated higher niclosamide-induced cytotoxicity in aldehyde
dehydrogenase (ALDH)-enriched non-adherent cells, compared with adherent cells from basal-like
breast cancers [120]. Again, niclosamide reduced levels of LRP6 and β-catenin. In combination with
TRA-8, an antibody specific to TNF-related apoptosis-inducing ligand (TRAIL) death receptor 5, Wnt
signaling was further reduced, in vitro cytotoxicity was enhanced, and growth of orthotopic tumor
xenografts was suppressed. The authors conclude that niclosamide or its congeners might be beneficial
for the treatment of basal-like breast cancers. The effect of niclosamide as a potential therapeutic agent
interfering with the Wnt signaling pathway was also investigated for ovarian cancer [121]. The authors
treated tumor cells isolated from patients’ ascites with primary ovarian cancer and showed increased
cytotoxicity, reduction of Wnt/β-catenin signaling by TOP assay, and decreased Wnt pathway proteins
e.g., Axin2 and cyclin D1. The authors evaluate niclosamide as a potent Wnt/β-catenin inhibitor
and as a treatment option for ovarian cancer. King and colleagues also investigated niclosamide
effects in ovarian cancer models [122]. Niclosamide abrogated Wnt7A/β-catenin signaling, inhibited
β-catenin transcriptional activity and cell viability, and decreased cell migration following an increase
in E-cadherin and a decrease of SLUG. Niclosamide applied orally inhibited tumor growth and
progression in an intraperitoneal xenograft mouse model representative of human ovarian cancer,
suggesting niclosamide as a promising inhibitor of this pathway with potential clinical relevance.
Recently, Satoh and colleagues identified niclosamide as most promising candidate by HTS for
adrenocortical carcinoma [123]. The authors demonstrated that niclosamide inhibited cell proliferation,
induced caspase-dependent apoptosis and G1 cell cycle arrest, and decreased cell migration. It also
reduced the level of mediators of epithelial-to-mesenchymal transition, decreased expression of
β-catenin, and inhibited tumor growth with no observed toxicity in mice.
Niclosamide and Further Signaling Pathways
Although all of these studies demonstrate the interference of niclosamide in the Wnt signaling
pathway, leading to reduced target gene expression and resulting in reduced cell proliferation and
motility in several cancer types, it has to be mentioned that niclosamide is able to block multiple
signaling pathways, which play a major role in cancer initiation, progression, and metastasis in a panel
of different cancer types. This broad anti-cancer activity is also reflected by a screen with niclosamide
on the NCI-60 human tumor cell line panel [124]. Niclosamide was able to inhibit cell proliferation of
all lines with IC50 values below 1 µM [125]. Several groups investigated the effects of niclosamide to
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multiple signaling pathways in addition or besides the Wnt signaling pathway. Osada and colleagues
identified the Wnt signaling to be targeted by niclosamide and excluded niclosamide-mediated
inhibition of NFκB or mTOR pathways in their CRC model systems [117]. Despite intervening in the
Wnt signaling pathway it was demonstrated in the last years that niclosamide is able to block different
pathways in different cancer types (reviewed for cancer cells and cancer stem cells in [125,126]):
niclosamide inhibited the transcription factors E2F1 and AP1, and c-myc-responsive reporters, whereas
the hypoxia-inducible factor (HIF) 1α, TCF/LEF, cyclic AMP-responsive element-binding (CREB),
NFκB, SMAD/TGF-β, and recombining binding protein suppressor of hairless (RBPJ)/neurogenic
locus notch homolog protein (Notch) pathway reporters were inhibited to a lesser extend in human
osteosarcoma cells [127]; inhibited the mTOR complex 1 pathway activity by lysosomal dysfunction in
different cancer types [128–130]; inhibited signal transducer and activator of transcription (STAT) 3 in
head and neck cancer cells and in NSCLC cells [131,132], and blocked STAT3 phosphorylation and its
translocation into the nucleus in prostate cancer cells [133]; inactivated the NFκB pathway in acute
myelogenous leukemia stem cells [134], and simultaneously inhibited Wnt/β-catenin, Notch, mTOR,
and NFκB signaling cascades in human glioblastoma [135].
Niclosamide and Derivatives
Based on the promising anti-cancer effects of niclosamide, niclosamide chemotypes have been
identified or synthesized, and tested for their anti-cancer effects and for their interference with the
Wnt signaling pathway. When we discovered the anti-migratory and anti-invasiveness effects of
niclosamide via inhibiting the Wnt signaling pathway and the metastasis gene S100A4, we extended
our analyses to structural derivatives of this drug [104]. In contrast to the effects of niclosamide
itself, we did neither observe reduced levels of S100A4 mRNA and protein levels nor reduced
cell migration with any of the six niclosamide derivatives analyzed so far. Thus, changes in the
structure of niclosamide described in our study resulted in loss of its efficiency toward inhibition of
S100A4 expression and cell motility. Mook and colleagues also found inhibition of Wnt signaling by
niclosamide appears unique among the structurally-related anti-helminthic agents they tested [136].
They showed the potency and functional response was dependent on small changes in the chemical
structure of niclosamide. The same group published two years later their structure-activity studies of
Wnt/β-catenin inhibition by different niclosamide chemotypes [137]. The authors investigated the
structure-activity relationships of Wnt signaling inhibition in the anilide and salicylamide region of
niclosamide. They identified drug candidates for treating cancers with dysregulated Wnt signaling,
including drug-resistant cancers. Walters Haygood and colleagues tested more soluble niclosamide-like
analogs on tumorspheres from ovarian cancer patient ascites and slices from solid tumor samples [138].
They found down-regulation of Wnt pathway-associated proteins in the patient samples treated with
niclosamide analogs, suggesting these compounds may be useful for the treatment of ovarian cancer.
Taken together, these newly developed niclosamide analogs act in cell culture, in mice, as well as in
patient samples by intervening in the Wnt/β-catenin signaling pathway [137,138].
Niclosamide in Clinical Trials
Based on the niclosamide-related findings reviewed here, we now aim at the repositioning of the
anti-helminthic drug niclosamide as anti-cancer agent for the clinical treatment or prevention of colon
cancer metastasis. Niclosamide is well tolerated in humans, approved for human use, and 2 g are
administered daily in adults to treat tapeworm infections. We are translating our findings on restricting
S100A4-driven metastasis into clinical practice. Together with the Charité Comprehensive Cancer
Center, we are evaluating the repositioned FDA-approved drug niclosamide targeting Wnt signaling
for treatment of CRC patients in a prospective phase II clinical trial: Drug Trial to Investigate the Safety
and Efficacy of Niclosamide Tablets in Patients with Metastases of a Colorectal Cancer Progressing
after Therapy (Nikolo). This clinical trial is registered with ClinicalTrials.gov (NCT02519582) and the
European Clinical Trials Database (EudraCT 2014-005151-20). We initiated this first phase II clinical
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trial in August 2015 evaluating the safety and efficacy of orally applied niclosamide in patients who
are progressive with metachronous or synchronous metastases of CRC after the previous therapy.
Two grams niclosamide per day are given to the CRC patients of this monocentric open-label clinical
trial, received until progression (according to RECIST = Response Evaluation Criteria in Solid tumor)
or unacceptable toxicity. The primary endpoint is the progression-free survival (PFS) at 4 months.
Secondary outcome measures are overall survival (date of randomization until date of death, assessed
up to 2 years, or date from patient inclusion to date of death or date of last follow-up news, censured
data), time to progression (date of randomization until date of first documented progression, assessed
up to 2 years; progression according to RECIST criteria), disease control rate (date of randomization,
assessed up to 2 years, remission/partial remission/stable disease), the number of adverse events
> grade 2 toxicities according to NCI Common Toxicity Criteria for Adverse Effects v4.03 (date of
randomization, assessed up to 1 month after end of therapy), and the number of serious adverse
events (date of randomization, assessed up to 1 month after end of therapy). The first patients are
already enrolled; a total of 37 patients will be enrolled in this interventional trial. The primary outcome
measure, PFS at 4 months, will be analyzed in a first evaluation after treatment of the first 17 patients.
Paralleling this clinical trial, translational research is performed, e.g., determining S100A4 expression
in tumor tissues and metastases, and monitoring treatment success by quantifying the circulating
S100A4 transcripts in patient blood. The trial is planned to be completed in February 2018.
Very recently, in February 2016, another clinical trial testing niclosamide in CRC patients was
initiated by the Duke University Medical Center: A Study of Niclosamide in Patients with Resectable
Colon Cancer. This clinical trial is registered with ClinicalTrials.gov (NCT02687009). The authors are
performing this phase I clinical trial to obtain safety data along with pharmacokinetic data and with
the determination of the maximum tolerated dose (three dosage levels of niclosamide) in patients with
colon cancer who undergo primary resection of their tumor. Further, they wish to obtain information on
the changes in the Wnt pathway signaling following niclosamide administration in humans. They aim
at future studies in patients with more advanced CRC or other cancers with dysregulation of the
Wnt pathway.
Taken together, these recently initiated clinical trials will provide first insights in the
niclosamide-induced inhibition of Wnt/β-catenin signaling and the clinical consequences thereof. The
outcome of these clinical trials on niclosamide for treatment of CRC patients will contribute to the
evaluation of the repositioning of this anti-helminthic drug niclosamide for the clinical treatment or
prevention of CRC metastasis.
4. Conclusions
Metastasis formation is the major hurdle in CRC therapy. To identify patients at high risk for
metastasis formation, early diagnosis and molecular characterization of the primary tumor is crucial
to define prognostic and therapeutic targets. S100A4 has been shown to contribute to both demands
in CRC: serving as biomarker, which allows the prognosis of patient survival and metachronous
metastasis already in early stages being determined in tumor tissue or non-invasively in liquid biopsies;
and serving as therapeutic target, since its down-regulation by e.g., small molecules restricts metastasis
formation in mice and is currently tested in clinical trials. Other strategies of therapeutic interventions
tested in preclinical studies, like S100A4-specific antibodies or drug/peptide-based interference of
S100A4-protein interactions, further point to the relevance of treating CRC by targeting S100A4.
As S100A4 is a direct target of β-catenin/TCF-mediated transcription in CRC, interfering in
the Wnt signaling pathway thereby reducing expression and/or nuclear accumulation of β-catenin
has emerged as new option to restrict S100A4-induced cell motility and metastasis. Promising,
already FDA-approved drugs were identified to reduce β-catenin-mediated S100A4 gene transcription
resulting in diminished cellular motility in vitro and metastasis formation in vivo and are currently
evaluated in clinical trials to reduce the risk of metastasis formation in CRC thereby improving patient
survival and quality of life. In recent years, further approaches have been demonstrated to interfere
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with the Wnt signaling pathway upstream of β-catenin [139,140]. Their usefulness, however, to restrict
S100A4-induced cell motility and metastasis remains to be demonstrated. It might be anticipated
that a combinatorial treatment using drugs such as the FDA-approved and repositioned compounds
discussed in this review together with inhibitors acting upstream of β-catenin and thus targeting the
Wnt signaling pathway at different levels might be most efficient for the patients.
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Abbreviations
The following abbreviations are used in this manuscript:
APC adenomatous polyposis coli
ChIP chromatin immunoprecipitation
CK casein kinase
CMV cytomegalovirus
COX cyclooxygenase
CRC colorectal cancer
DKK Dickkopf-related protein
Dvl segment polarity protein dishevelled homolog
EMSA electrophoretic mobility shift assay
EMT epithelial-mesenchymal transition
ERBB2 receptor tyrosine-protein kinase erbB-2
ERK extracellular signal-regulated kinase
FDA Food and Drug Administration
GOF gain-of-function
GSK glycogen synthase kinase
HTS high throughput screening
IC50 half maximal inhibitory concentration
LEF lymphoid enhancer-binding factor
LOPAC Library of Pharmacologically Active Compounds
LRP low-density lipoprotein receptor-related protein
MACC1 metastasis associated in colon cancer 1
MMP matrix metalloproteinase
mRNA messenger RNA
NFκB nuclear factor kappa-light-chain-enhancer of activated B cells
Notch neurogenic locus notch homolog protein
NSAID nonsteroidal anti-inflammatory drug
NSCLC non-small cell lung cancer
PCR polymerase chain reaction
PFS progression-free survival
RAGE receptor for advanced glycation end products
RECIST response evaluation criteria in solid tumor
RNA ribonucleic acid
RNAi RNA interference
S100A4 S100 calcium binding protein A4
si/shRNA small interfering/hairpin RNA
SMAD mothers against decapentaplegic homolog
STAT signal transducer and activator of transcription
TCF T-cell factor
TGF transforming growth factor
TIMP tissue inhibitor of metalloproteinases
VEGF vascular endothelial growth factor
Wnt wingless-type MMTV integration site family member
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